The estimated Net Worth of Richard L Harrison is at least 2.44 百万$ dollars as of 12 January 2017. Richard Harrison owns over 20,634 units of Glaukos stock worth over 966,476$ and over the last 9 years Richard sold GKOS stock worth over 1,475,400$.
Richard has made over 8 trades of the Glaukos stock since 2015, according to the Form 4 filled with the SEC. Most recently Richard exercised 20,634 units of GKOS stock worth 150,216$ on 12 January 2017.
The largest trade Richard's ever made was selling 30,000 units of Glaukos stock on 3 May 2016 worth over 737,700$. On average, Richard trades about 11,151 units every 34 days since 2015. As of 12 January 2017 Richard still owns at least 7,701 units of Glaukos stock.
You can see the complete history of Richard Harrison stock trades at the bottom of the page.
Richard's mailing address filed with the SEC is C/O GLAUKOS CORPORATION, 20651 MERIT CIRCLE, SUITE 103, LAGUNA HILLS, CA, 92653.
Over the last 11 years, insiders at Glaukos have traded over 300,254,118$ worth of Glaukos stock and bought 17,376 units worth 317,262$ . The most active insiders traders include Advisors Llc Orbi Med Capit...、Gilbert H Kliman、Jonathan Silverstein. On average, Glaukos executives and independent directors trade stock every 25 days with the average trade being worth of 8,240,079$. The most recent stock trade was executed by Gilbert H Kliman on 9 September 2024, trading 3,000 units of GKOS stock currently worth 96,000$.
glaukos corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures to transform the treatment of glaucoma, one of the world’s leading causes of blindness. glaukos has pioneered micro-invasive glaucoma surgery, or migs, to revolutionize the traditional glaucoma treatment and management paradigm. the company launched the istent trabecular micro-bypass stent, its first migs device, in the united states in 2012. glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression. glaukos believes the istent is the smallest medical device ever approved by the food and drug administration, or fda, measuring 1.0 mm long and 0.33 mm wide. in june 2015, the company completed an initial public offering and its shares are now traded on the new york stock exchange unde
Glaukos executives and other stock owners filed with the SEC include: